Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07067437
Recruiting Not applicable

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437 · tracked via the Priya Life Science Switzerland tracker
Sponsor
National Institute of Oncology, Hungary
Phase
Not applicable
Started
2025-07-01
Last updated
2026-09-09

Condition(s) studied

Breast Neoplasms

Investigational drug(s) / intervention(s)

single-fraction very accelerated partial breast irradiation

single-fraction very accelerated partial breast irradiation: Adjuvant accelerated partial breast brachytherapy, with interstitial multicatheter technique, in one fraction.

Study summary

To investigate clinical outcomes, late side effects, and cosmetic results of a single-fraction very accelerated partial breast irradiation as postoperative local treatment for the treatment of early stage breast cancer.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Stage 0 \& I \& II (\< 3 cm) breast carcinoma * Lesions of \< 3 cm diameter * Invasive carcinoma of any subtype and grade or ductal carcinoma in situ (DCIS) * Nodal status: node-negative (pN0) or micro-metastatic (pN1mi) (patients with pN1mi status can be treated, but due to the limited clinical evidence, individual decision is needed) * M0: Absence of distant metastasis * Clear resection margins by National Surgical Adjuvant Breast and Bowel Project (NSABP) definition (no tumor on ink) * Unifocal (multifocality limited within 2 cm) and unicentric breast cancer * Age\> 40 years * Luminal A or B tumors * Time interval from surgery preferably less than 12 weeks and no longer than 20 weeks, and from adjuvant chemotherapy less than 4 weeks * Human Epidermal growth factor Receptor 2 positive (HER2+) patients receiving postoperative anti-HER2 systemic therapy * Specific signed consent form prior to randomization Exclusion Criteria: * Stage III-IV breast cancer * Surgical margins that cannot be microscopically assessed * Extensive intraductal component (EIC+) * Extensive lymphovascular invasion (LVI+) (focal is allowed) * Triple negative breast cancer * BReast CAncer gene (BRCA) 1-2 mutation * Human Epidermal growth factor Receptor 2 positive (HER2+) patients not receiving postoperative anti-HER2 systemic therapy * Neoadjuvant systemic therapy * Paget's disease or pathological skin involvement * Synchronous or previous breast cancer. * Pregnant or lactating women

Primary outcome measure(s)

Trial sites (23)

FacilityCityRegionStatus
Centre Léon Bérard Lyon France Not Yet Recruiting
Institut de Cancérologie de Lorraine Nancy France Not Yet Recruiting
Antoine Lacassagne Cancer Centre Nice France Recruiting
Klinikum Bremerhaven Bremerhaven Germany Not Yet Recruiting
University Hospital Erlangen Erlangen Germany Recruiting
Universitätsklinikum Schleswig-Holstein Lübeck Germany Not Yet Recruiting
Sana Klinikum Offenbach Offenbach Germany Not Yet Recruiting
Universitätsklinikum Würzburg Würzburg Germany Not Yet Recruiting
National Institute of Oncology Budapest Hungary Recruiting
National Cancer Institute Vilnius Lithuania Not Yet Recruiting
Maria Skłodowska-Curie Bialystok Oncology Center Bialystok Poland Not Yet Recruiting
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny Brzozów Poland Not Yet Recruiting
National Institute of Oncology Gliwice Poland Recruiting
Greater Poland Cancer Centre Poznan Poland Recruiting
Lower Silesian Oncology, Pulmonology and Hematology Center Wroclaw Poland Not Yet Recruiting
Instituto Português de Oncologia do Porto Porto Portugal Not Yet Recruiting
Oncology Institute Vojvodina Kamenica Serbia Recruiting
Hospital del Mar Barcelona Spain Recruiting
Fundacion IMOR's Oncology Clinic Barcelona Spain Not Yet Recruiting
Institut Catala d'Oncologia Barcelona Spain Recruiting
Hospital Universitario de Navarra Pamplona Spain Not Yet Recruiting
Instituto Valenciano de Oncologia Valencia Spain Not Yet Recruiting
Inselspital, Universitätsspital Bern Bern Switzerland Not Yet Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07067437 on ClinicalTrials.gov ↗ ← All trials in Switzerland